NasdaqGM - Delayed Quote USD

MannKind Corporation (MNKD)

4.2300 +0.0500 (+1.20%)
At close: April 26 at 4:00 PM EDT
4.2800 +0.05 (+1.18%)
After hours: April 26 at 4:45 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
198,962.0000
198,962.0000
99,770.0000
75,442.0000
65,144.0000
Cost of Revenue
62,771.0000
62,771.0000
57,497.0000
38,857.0000
24,641.0000
Gross Profit
136,191.0000
136,191.0000
42,273.0000
36,585.0000
40,503.0000
Operating Expense
125,597.0000
125,597.0000
111,194.0000
90,068.0000
65,288.0000
Operating Income
10,594.0000
10,594.0000
-68,921.0000
-53,483.0000
-24,785.0000
Net Non Operating Interest Income Expense
-19,007.0000
-19,007.0000
-22,256.0000
-16,465.0000
-9,304.0000
Other Income Expense
-1,964.0000
-1,964.0000
3,777.0000
-10,978.0000
-23,369.0000
Pretax Income
-10,377.0000
-10,377.0000
-87,400.0000
-80,926.0000
-57,458.0000
Tax Provision
1,561.0000
1,561.0000
--
--
-218.0000
Net Income Common Stockholders
-11,938.0000
-11,938.0000
-87,400.0000
-80,926.0000
-57,240.0000
Diluted NI Available to Com Stockholders
-11,938.0000
-11,938.0000
-87,400.0000
-80,926.0000
-57,240.0000
Basic EPS
-0.04
--
-0.34
-0.32
-0.26
Diluted EPS
-0.04
--
-0.34
-0.32
-0.26
Basic Average Shares
267,014.0000
--
257,092.0000
249,244.0000
222,585.0000
Diluted Average Shares
267,014.0000
--
257,092.0000
249,244.0000
222,585.0000
Total Operating Income as Reported
8,678.0000
8,678.0000
-64,110.0000
-47,022.0000
-47,913.0000
Total Expenses
188,368.0000
188,368.0000
168,691.0000
128,925.0000
89,929.0000
Net Income from Continuing & Discontinued Operation
-11,938.0000
-11,938.0000
-87,400.0000
-80,926.0000
-57,240.0000
Normalized Income
-10,290.0600
-10,290.0600
-91,279.0000
-70,187.0000
-33,941.5680
Interest Income
6,154.0000
6,154.0000
2,513.0000
112.0000
167.0000
Interest Expense
25,161.0000
25,161.0000
24,769.0000
16,577.0000
9,471.0000
Net Interest Income
-19,007.0000
-19,007.0000
-22,256.0000
-16,465.0000
-9,304.0000
EBIT
14,784.0000
14,784.0000
-62,631.0000
-64,349.0000
-47,987.0000
EBITDA
20,620.0000
20,620.0000
-56,319.0000
-61,105.0000
-44,661.0000
Reconciled Cost of Revenue
62,771.0000
62,771.0000
57,497.0000
38,857.0000
24,641.0000
Reconciled Depreciation
5,836.0000
5,836.0000
6,312.0000
3,244.0000
3,326.0000
Net Income from Continuing Operation Net Minority Interest
-11,938.0000
-11,938.0000
-87,400.0000
-80,926.0000
-57,240.0000
Total Unusual Items Excluding Goodwill
-2,086.0000
-2,086.0000
3,879.0000
-10,739.0000
-23,392.0000
Total Unusual Items
-2,086.0000
-2,086.0000
3,879.0000
-10,739.0000
-23,392.0000
Normalized EBITDA
22,706.0000
22,706.0000
-60,198.0000
-50,366.0000
-21,269.0000
Tax Rate for Calcs
0.0002
0.0002
--
--
0.0000
Tax Effect of Unusual Items
-438.0600
-438.0600
--
--
-93.5680
12/31/2020 - 7/28/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

UTHR United Therapeutics Corporation
233.85
-0.89%
 
LQDA Liquidia Corporation
12.53
+1.29%
 
GERN Geron Corporation
3.7900
+6.46%
 
AKBA Akebia Therapeutics, Inc.
1.3400
+0.75%
 
VSTM Verastem, Inc.
9.38
+1.79%
 
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
 
NRXP NRx Pharmaceuticals, Inc.
3.5400
+12.74%
 
FGEN FibroGen, Inc.
1.0400
+1.96%
 
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%
 
ARDX Ardelyx, Inc.
6.42
+1.74%